FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Dunne Michael W.</u>					2. Issuer Name and Ticker or Trading Symbol Aviragen Therapeutics, Inc. [AVIR]							Relationship of the contract o	cable)	g Pers	on(s) to Issi 10% Ow		
(Last) 2500 NC	`	irst) OS PARKWAY	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/18/2017							Officer below)	(give title		Other (s below)	pecify
STE 100				4. 1	If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) ALPHARETTA GA 30009												X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	State)	(Zip)														
		Tab	le I - Non	-Deriv	vativ	e Se	curities	s Ac	quired, Di	sposed (of, or Be	neficial	ly Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					ear) i	2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Disposed Code (Instr. 5)		ities Acquired (A) o d Of (D) (Instr. 3, 4		Beneficia	s ally following	Form (D) or	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code V	Amount	(A) oi (D)	Price	Transact (Instr. 3 a	ion(s)			(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate,	4. Transa Code (i 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$0.49	05/18/2017			A		20,000		05/18/2018	05/18/2027	Common Stock	20,000	\$0.49	75,000	0	D	

Explanation of Responses:

/s/ Mark Colonnese attorney-in-05/22/2017 fact for Michael Dunne

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.